VAERS Explorer
Back to explore

Report #2836222

Received Apr 15, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
77 yrs
State
NM
Recovered
Unknown
Vaccinated
Apr 10, 2025
Onset
Apr 10, 2025
Days to onset
0
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
TDAPTDAP (BOOSTRIX)GLAXOSMITHKLINE BIOLOGICALSUNK—OT
TDAPTDAP (ADACEL)SANOFI PASTEURUNK2CA69C1OT / LA

Symptoms (2)

No adverse eventProduct administered to patient of inappropriate age

Symptom narrative

Boostrix should still be given to a patient that was incorrectly administered with ADACEL with no adverse event; Initial information received on 10-Apr-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 77 years old male patient to whom vaccine Diphtheria-2/Tetanus/5 AC Pertussis Vaccine [Adacel] was incorrectly administered instead of being administered with Diphtheria Vaccine Toxoid, Pertussis Vaccine Acellular 3-Component, Tetanus Vaccine Toxoid (Boostrix) with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 10-Apr-2025 at 01:20 pm, the patient received a 0.5 ml dose of suspect Diphtheria-2/Tetanus/5 AC Pertussis Vaccine Suspension for injection (strength: standard, Frequency: once, expiry date: 20-Jul-2025 and lot 2CA69C1) via intramuscular route in the left arm as prophylactic vaccination (immunization) instead of Boostrix with no adverse event (wrong product administered) (latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.